This report is a prespecified subgroup analysis of the REC-CAGEFREE II trial, conducted at 41 sites in China. The parent trial randomized 1,948 participants with acute coronary syndrome (ACS) who underwent exclusively drug-coated balloon (DCB) angioplasty to either stepwise dual antiplatelet therapy (DAPT) de-escalation or standard DAPT. The current analysis stratified participants by angiographic vessel status into multivessel and single-vessel disease subgroups to examine whether vessel involvement modified clinical outcomes.
The primary endpoint for this analysis was net adverse clinical events (NACE) at 12 months. NACE was defined as a composite of all-cause death, stroke, myocardial infarction, revascularization, and BARC type 3 or 5 bleeding. Vessel status (multivessel vs single-vessel) was determined by angiographic characteristics reported in the trial dataset.
Among the 1,948 randomized participants, 720 patients (37.0%) had angiographic multivessel disease. The remaining cohort were classified as single-vessel disease. Baseline and procedural details beyond vessel distribution were reported in the trial but are not detailed in this subgroup summary.
At 12 months, patients with multivessel disease experienced higher absolute NACE rates compared with patients with single-vessel disease: 12.5% versus 6.7%. After adjustment using inverse probability of treatment weighting (IPTW), the hazard ratio for NACE in multivessel versus single-vessel disease was 1.84 (95% CI 1.35–2.51), P < 0.001, indicating a significantly elevated risk associated with multivessel involvement in this DCB-treated ACS population.
In the subgroup of patients with multivessel disease (n = 720), NACE occurred in 44 of 368 patients (12.1%) assigned to stepwise DAPT de-escalation and in 45 of 352 patients (12.9%) assigned to standard DAPT. The IPTW-adjusted hazard ratio comparing stepwise de‑escalation with standard DAPT was 0.95 (95% CI 0.62–1.75), P = 0.818, indicating no statistically significant difference in the primary composite endpoint between the two antiplatelet strategies within the multivessel group.
Among participants with single‑vessel disease, NACE occurred in 43 of 607 patients (7.1%) in the stepwise de‑escalation arm and 39 of 621 patients (6.3%) in the standard DAPT arm. The IPTW-adjusted hazard ratio was 1.12 (95% CI 0.72–1.70), P = 0.611, likewise showing no statistically significant difference between strategies in the single‑vessel subgroup.
The analysis tested for interaction between vessel status (multivessel versus single‑vessel) and treatment allocation with respect to the primary endpoint. No significant interaction was observed (Pinteraction = 0.542), implying that the relative effect of stepwise DAPT de‑escalation versus standard DAPT on NACE was consistent across vessel-status subgroups.
For the prespecified hierarchical secondary endpoint, win‑ratio analyses produced more wins for stepwise de‑escalation in both multivessel and single‑vessel subgroups. The source reports this finding but does not provide detailed component-level win-ratio statistics in the summary text.
Safety events contributing to NACE included ischemic outcomes and BARC type 3 or 5 bleeding; the composite endpoint was used to balance ischemic and bleeding risks. Competing interests were disclosed: P.W.S. reported consulting fees from several industry entities; Chao Gao and Ming Yuan reported funding sources; all other authors declared no competing interests. The trial was registered (ClinicalTrials.gov NCT04971356), approved by the Xijing Hospital ethics committee (ID: KY20212080-F-1) and other participating site committees, and all participants provided written informed consent. The source indicates that supporting data are available from the corresponding author upon reasonable request.
In ACS patients treated with DCB-only angioplasty, the presence of multivessel disease was associated with a significantly higher 12‑month risk of NACE compared with single‑vessel disease (12.5% vs 6.7%; HR IPTW 1.84, 95% CI 1.35–2.51).
There was no significant difference in 12‑month NACE between stepwise DAPT de‑escalation and standard DAPT in either the multivessel subgroup (12.1% vs 12.9%; HR IPTW 0.95, 95% CI 0.62–1.75) or the single‑vessel subgroup (7.1% vs 6.3%; HR IPTW 1.12, 95% CI 0.72–1.70).
No interaction between vessel status and treatment allocation was observed (Pinteraction = 0.542), suggesting similar relative effects of the two DAPT strategies regardless of disease extent.
Win‑ratio secondary analyses favored stepwise de‑escalation in both subgroups, although detailed component results were not provided in the summary.
These findings indicate that while multivessel disease identifies a higher‑risk population following DCB-only angioplasty in ACS, choice between stepwise DAPT de‑escalation and standard DAPT produced similar composite outcomes at 12 months in both vessel-status subgroups. Clinicians should interpret these subgroup results in the context of the full trial data and individual patient ischemic and bleeding risk profiles. For access to the trial dataset or additional subgroup details, the source indicates data are available from the corresponding author on reasonable request.